Bioceltix Company Description

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use.

Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses.

The company was incorporated in 2018 and is based in Wroclaw, Poland.

Bioceltix S.A.

Country	Poland
Founded	2018
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Lukasz Bzdzion

Contact Details

Address: Building III Wroclaw, 51-317 Poland
Phone	48 71 880 8771
Website	bioceltix.com

Stock Details

Ticker Symbol	BCX
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLBCLTX00019
SIC Code	2836

Key Executives

Name	Position
Lukasz Bzdzion	President of the Management Board
Dr. Pawel Wielgus	Member of the Management Board
Andrij Wlach	Chief Financial Officer
Grzegorz Ostropolski	Chief Operating Officer
Dr. Jakub Grzesiak Ph.D.	Technology Director